| Code | CSB-RA012352MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to lirilumab, targeting KIR2DL1 (Killer Cell Immunoglobulin-Like Receptor 2DL1), an inhibitory receptor expressed on natural killer (NK) cells and certain T cell subsets. KIR2DL1 binds to HLA-C group 2 allotypes on target cells, delivering inhibitory signals that prevent NK cell activation and cytotoxic responses. This regulatory mechanism is critical for self-tolerance but can be exploited by tumor cells to evade immune surveillance. Aberrant KIR2DL1 expression and signaling have been implicated in various malignancies, including acute myeloid leukemia, multiple myeloma, and solid tumors, where tumor cells use HLA-C interactions to suppress NK cell-mediated cytotoxicity.
Lirilumab was developed as a fully humanized IgG4 monoclonal antibody designed to block KIR2DL1-mediated inhibition, thereby enhancing NK cell activity against cancer cells. This biosimilar provides researchers with a valuable tool for investigating NK cell biology, KIR-HLA interactions, and immune checkpoint mechanisms in oncology and immunology research. It supports studies exploring novel immunotherapeutic strategies and mechanisms of tumor immune evasion.
There are currently no reviews for this product.